CUMULATIVE ECONOMIC AND SOCIETAL BURDEN OF GRADE 2 MIDH GLIOMA ON PATIENTS AND CAREGIVERS, STRATIFIED BY RADIOTHERAPY/CHEMOTHERAPY EXPOSURE
Author(s)
Celine Aubin, PharmD, MSc1, Anais RAGON, PharmD, MSc1, Slávka Lukacova, MD2, Aida Muhic, MD3, Jane Skjøth-Rasmussen, MD3, Oskar Strom, PhD4, Morten Johnsen, PhD5.
1Les Laboratoires Servier, Suresnes, France, 2Aarhus University Hospital, Aarhus, Denmark, 3Copenhagen University Hospital, Copenhagen, Denmark, 4i3 Innovus, Stockholm, Sweden, 5Quantify Research, Copenhagen, Denmark.
1Les Laboratoires Servier, Suresnes, France, 2Aarhus University Hospital, Aarhus, Denmark, 3Copenhagen University Hospital, Copenhagen, Denmark, 4i3 Innovus, Stockholm, Sweden, 5Quantify Research, Copenhagen, Denmark.
OBJECTIVES: This study evaluated the 10-year cumulative socioeconomic and societal burden in patients with Grade 2 IDH-mutant (mIDH) glioma and their partners, focusing on radiotherapy (RT) / chemotherapy (CT) exposure as a clinically meaningful inflection point.
METHODS: This longitudinal cohort study used pseudonymized Danish administrative registry data. Patients with Grade 2 mIDH glioma not in immediate need of RT/CT and their partners were identified and matched 1:5 to general population controls. Outcomes were assessed over a 10-year follow-up period and included income, work absenteeism, healthcare costs, psychiatric diseases.
RESULTS: N=237 patients (n=1161 controls) and n=113 partners (n=550 controls) were included. Mean patient age was 40 years. By year 10, n=64 patients (n=301 controls) were still alive and followed and 52% had received RT/CT. Patients experienced significant 10-year cumulative burden vs. matched controls: -36% (-€162,919; p<0.001) in pay-check income, +127% (+€82,896; p<0.001) in added public benefits, +719% (+€91,519; p<0.001) in healthcare costs, and +644% (+€172,867; p<0.001) in productivity losses. RT/CT exposed patients showed markedly worse trajectories, with higher accumulated public benefits (+€117,972; +183%) and productivity loss (+€265,442; 12.7x controls) vs. non-exposed patients (+€45,559; +69% in public benefit and +€66,620; 3.1x controls productivity loss). 10 years cumulative healthcare costs were approximately doubled in RT/CT exposed (€144,748) vs. non-exposed patients (€61,134). Overall partners of glioma patients remained employed. Over 10 years, partners of non-exposed patients approximately followed their controls. Conversely, RT/CT exposed patient partners exhibited approximately two times higher work absenteeism and productivity losses, and heightened healthcare costs, highlighting a broader caregiver burden.
CONCLUSIONS: Grade 2 mIDH glioma profoundly impacts patients’ long-term socioeconomic status. Exposure to RT/CT emerges as a critical milestone for worsened outcomes. Delaying the need for RT/CT through innovative therapeutic strategies may help preserve patients' ability to work and improve their overall quality of life, alongside mitigating the broader societal caregiver burden.
METHODS: This longitudinal cohort study used pseudonymized Danish administrative registry data. Patients with Grade 2 mIDH glioma not in immediate need of RT/CT and their partners were identified and matched 1:5 to general population controls. Outcomes were assessed over a 10-year follow-up period and included income, work absenteeism, healthcare costs, psychiatric diseases.
RESULTS: N=237 patients (n=1161 controls) and n=113 partners (n=550 controls) were included. Mean patient age was 40 years. By year 10, n=64 patients (n=301 controls) were still alive and followed and 52% had received RT/CT. Patients experienced significant 10-year cumulative burden vs. matched controls: -36% (-€162,919; p<0.001) in pay-check income, +127% (+€82,896; p<0.001) in added public benefits, +719% (+€91,519; p<0.001) in healthcare costs, and +644% (+€172,867; p<0.001) in productivity losses. RT/CT exposed patients showed markedly worse trajectories, with higher accumulated public benefits (+€117,972; +183%) and productivity loss (+€265,442; 12.7x controls) vs. non-exposed patients (+€45,559; +69% in public benefit and +€66,620; 3.1x controls productivity loss). 10 years cumulative healthcare costs were approximately doubled in RT/CT exposed (€144,748) vs. non-exposed patients (€61,134). Overall partners of glioma patients remained employed. Over 10 years, partners of non-exposed patients approximately followed their controls. Conversely, RT/CT exposed patient partners exhibited approximately two times higher work absenteeism and productivity losses, and heightened healthcare costs, highlighting a broader caregiver burden.
CONCLUSIONS: Grade 2 mIDH glioma profoundly impacts patients’ long-term socioeconomic status. Exposure to RT/CT emerges as a critical milestone for worsened outcomes. Delaying the need for RT/CT through innovative therapeutic strategies may help preserve patients' ability to work and improve their overall quality of life, alongside mitigating the broader societal caregiver burden.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE370
Topic
Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Work & Home Productivity - Indirect Costs
Disease
Oncology, Rare & Orphan Diseases